Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Clinical Manifestations and Prognostic Factors of Chronic Ocular Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation

Lan Y Wang, MD, Gloria B Chiu, OD, FAAO, FSLS, Rachel A Young, OD, Mojtaba Akhtari, MD

Blood (2018) 132 (Supplement 1): 5731.

https://doi.org/10.1182/blood-2018-99-119903

Published: 2018

Journal Articles

Long-Term Morbidity Associated with Chronic Graft Vs. Host Disease (cGvHD) - a Blood or Marrow Transplant Survivor Study (BMTSS)

Mukta Arora, MD, Yanjun Chen, Jessica Wu, BA, Lindsey Hageman, MPH, Liton F. Francisco, BS, Emily Ness, MPH, Mariel Parman, MPH, Michelle Kung, MA, Alysia Bosworth, BA, Manju Nayar, Ravi Bhatia, MD, Stephen J. Forman, MD FACP, Daniel J. Weisdorf, MD, Saro H. Armenian, DO,MPH, Smita Bhatia, MDMPH

Blood (2017) 130 (Supplement 1): 336.

https://doi.org/10.1182/blood.V130.Suppl_1.336.336

Published: 2017

Journal Articles

Idiopathic Hemochromatosis Presenting As a Sicca Syndrome. A Case Report and Review of the Literature

Bilawal Ahmed, MD, Beenish Zulfiqar, MD

Blood (2017) 130 (Supplement 1): 4757.

https://doi.org/10.1182/blood.V130.Suppl_1.4757.4757

Published: 2017

Journal Articles

X4P-001: A Novel Molecularly-Targeted Oral Therapy for Whim Syndrome

David Dale, MD, Audrey Anna Bolyard, RN, BS, Emily Dick, BA, Merideth L. Kelley, MS, Vahagn Makaryan, MD, Ramsey Johnson, MSM, Lu Gan, MD PhD, Sudha Parasuraman, MD

Blood (2017) 130 (Supplement 1): 995.

https://doi.org/10.1182/blood.V130.Suppl_1.995.995

Published: 2017

Journal Articles

Deep and Durable Responses in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (MM) Treated with Monotherapy GSK2857916, an Antibody Drug Conjugate Against B-Cell Maturation Antigen (BCMA): Preliminary Results from Part 2 of Study BMA117159

Suzanne Trudel, MD FRCP(C), Nikoletta Lendvai, MD PhD, Rakesh Popat, MD PhD, Peter M. Voorhees, MD, Brandi Reeves, MD, Edward N. Libby, III, MD, Paul G Richardson, MD, Larry Anderson, MD PhD, Heather Sutherland, MD, Kwee Yong, PhD, Axel Hoos, MD PhD, Michele Gorczyca, MS, Soumi Lahiri, PhD, Zangdong He, PhD, Roxanne C Jewell, PhD, Joanna B. Opalinska, MD PhD, Adam D. Cohen, MD

Blood (2017) 130 (Supplement 1): 741.

https://doi.org/10.1182/blood.V130.Suppl_1.741.741

Published: 2017

Journal Articles

Chemotherapy-Free Induction with Ibrutinib-Rituximab Followed By Shortened Cycles of Chemo-Immunotherapy Consolidation in Young, Newly Diagnosed Mantle Cell Lymphoma Patients: A Phase II Clinical Trial

Blood (2016) 128 (22): 147.

https://doi.org/10.1182/blood.V128.22.147.147

Published: 2016

Journal Articles

First in Human Study with GSK2857916, an Antibody Drug Conjugated to Microtubule-Disrupting Agent Directed Against B-Cell Maturation Antigen (BCMA) in Patients with Relapsed/Refractory Multiple Myeloma (MM): Results from Study BMA117159 Part 1 Dose Escalation

Adam D. Cohen, MD, Rakesh Popat, Suzanne Trudel, MD, Paul G Richardson, MD, Ed N. Libby, III, MD, Nikoletta Lendvai, MDPhD, Larry D. Anderson, Jr., MD PhD, Heather J. Sutherland, MD PhD, Stephen DeWall, Catherine E Ellis, Zangdong He, Jolly Mazumdar, Catherine Wang, Joanna B. Opalinska, MD PhD, Peter M. Voorhees, MD

Blood (2016) 128 (22): 1148.

https://doi.org/10.1182/blood.V128.22.1148.1148

Published: 2016

Journal Articles

Ocular Graft-Versus Host Disease Prevention with Topical Cyclosporine in Non-Myeloablative Allogeneic Stem Cell Transplant

Rosa Elena Lozano-Morales, MD, Alberto Vázquez-Mellado de Larracoechea, Olga Cantu-Rodriguez, MD, Juan Luis Gonzalez-Treviño, Perla Rocío Colunga-Pedraza, MD, Miguel Angel Herrera-Rojas, MD, Monica Sánchez-Cárdenas, David Martínez-Garza, Daniela Michelle Pérez-Garza, David Gomez-Almaguer, MD

Blood (2016) 128 (22): 4569.

https://doi.org/10.1182/blood.V128.22.4569.4569

Published: 2016

Journal Articles

Ibrutinib Plus Rituximab in Treatment-Naive Patients with Follicular Lymphoma: Results from a Multicenter, Phase 2 Study

Nathan Fowler, MD, Loretta Nastoupil, MD, Sven de Vos, MD PhD, Mark Knapp, MD, Ian W. Flinn, MD PhD, Robert Chen, Ranjana H Advani, MD, Sumeet Bhatia, MD, Peter Martin, MD, Raul Mena, MD, Samuel Suzuki, MS, MBA, Darrin M. Beaupre, MD, Jutta K. Neuenburg, MD, M. Lia Palomba, MD

Blood (2015) 126 (23): 470.

https://doi.org/10.1182/blood.V126.23.470.470

Published: 2015

Journal Articles

A Phase 1 Study of Denintuzumab Mafodotin (SGN-CD19A) in Relapsed/Refactory B-Lineage Non-Hodgkin Lymphoma

Craig H Moskowitz, Michelle A Fanale, Bijal D Shah, Ranjana H Advani, MD, Robert Chen, Stella Kim, Ana Kostic, Tina Liu, Joanna Peng, Andres Forero-Torres

Blood (2015) 126 (23): 182.

https://doi.org/10.1182/blood.V126.23.182.182

Published: 2015

Journal Articles

Clinical Manifestations and Treatment Results in Accordance with Frontline Treatment Modalities for Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma (OAML)

Young-Woo Jeon, Jae-Ho Yoon, MD, Sung-Eun Lee, MD, Ki-Seong Eom, Yoo-Jin Kim, Hee-Je Kim, MD, Seok Lee, Chang-Ki Min, MD, Jong Wook Lee, Woo-Sung Min, MD, Seok-Goo Cho, MD

Blood (2015) 126 (23): 1522.

https://doi.org/10.1182/blood.V126.23.1522.1522

Published: 2015

Journal Articles

Preliminary Safety and Efficacy of the Combination of Brentuximab Vedotin and Ipilimumab in Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412)

Catherine S. Diefenbach, MD, Fangxin Hong, PhD, Jonathon B. Cohen, MD, Michael J. Robertson, MD, Richard F. Ambinder, MD PhD, Timothy S. Fenske, MD, Ranjana H Advani, MD, Brad S Kahl, MD, Stephen Ansell, MD PhD

Blood (2015) 126 (23): 585.

https://doi.org/10.1182/blood.V126.23.585.585

Published: 2015

Journal Articles

Sorafenib Is Contributing to Salvage Chemotherapy and Is Effective Given Alone for Maintenance in AML FLT3 ITD Patients Relapsing Post Allo Hematopoietic Stem Cell Transplantation

Emilia Jaskula, PhD, Janusz Lange, MD PhD, Mariola Sedzimirska, MD PhD, Andrzej Lange, MD Dr MDSci., Professor

Blood (2014) 124 (21): 5265.

https://doi.org/10.1182/blood.V124.21.5265.5265

Published: 2014

Journal Articles

GvHD Kinetics after Haploidentical TK-Cells: In-Vivo HSV-TK Suicide Machinery Is Effective in GvHD Control and Provide a Long-Term Immune-Suppressive Treatment-Free Survival

Maria Teresa Lupo-Stanghellini, MD, Chiara Bonini, MD, Giacomo Oliveira, MSc, Attilio Bondanza, MD PhD, Luca Vago, MD PhD, Raffaella Greco, MD, Jacopo Peccatori, MD, Scialini Colombi, BSc, Antonio Lambiase, MD, Fabio Ciceri, MD, Claudio Bordignon, MD

Blood (2014) 124 (21): 548.

https://doi.org/10.1182/blood.V124.21.548.548

Published: 2014

Journal Articles

Ibrutinib and Rituximab Are an Efficacious and Safe Combination in Relapsed Mantle Cell Lymphoma: Preliminary Results from a Phase II Clinical Trial

Michael (Luhua) Wang, MD, Fredrick Hagemeister, MD, Jason R. Westin, MD, Luis Fayad, MD, Felipe Samaniego, MD, Francesco Turturro, MD, Wendy Chen, Liang Zhang, MD PhD, Maria Badillo, BS, Maria DeLa Rosa, Alicia Addison, Larry W. Kwak, MD PhD, Jorge E. Romaguera, MD

Blood (2014) 124 (21): 627.

https://doi.org/10.1182/blood.V124.21.627.627

Published: 2014

Journal Articles

Interim Analysis of a Phase 1 Study of the Antibody-Drug Conjugate SGN-CD19A in Relapsed or Refractory B-Lineage Non-Hodgkin Lymphoma

Craig H. Moskowitz, MD, Andres Forero-Torres, MD, Bijal D. Shah, MD, Ranjana Advani, MD, Paul Hamlin, MD, Stella Kim, MD, Ana Kostic, MD, Larissa Sandalic, MS, Baiteng Zhao, PhD, Michelle A. Fanale, MD

Blood (2014) 124 (21): 1741.

https://doi.org/10.1182/blood.V124.21.1741.1741

Published: 2014

Journal Articles

Interim Analysis of a Phase 1 Study of the Antibody-Drug Conjugate SGN-CD19A in Relapsed or Refractory B-Lineage Acute Leukemia and Highly Aggressive Lymphoma

Amir T Fathi, Robert Chen, MD, Tanya M. Trippett, Maureen M. O'Brien, MD, Daniel J DeAngelo, Bijal D. Shah, MD, Todd M. Cooper, DO, James M. Foran, MD, Gregory A. Hale, MD, Joseph Pressey, MD, Lewis B. Silverman, Raoul Tibes, MD, Stella Kim, MD, Tina M. Albertson, MD PhD, Larissa Sandalic, MS, Baiteng Zhao, PhD, Uma Borate, MD

Blood (2014) 124 (21): 963.

https://doi.org/10.1182/blood.V124.21.963.963

Published: 2014

Journal Articles

Recruitment Of T Cells and Macrophages To The Eyes In Recipients Of Allogeneic Hematopoietic Stem Cell Transplants Correlate With Inflammatory Cytokine Presence In Ocular Gvhd

Samantha Herretes, M.D., Juan C. Murillo, M.D., Duncan Ross, Ph.D., Tan Yaohong, M.D., Henry Barreras, B.S., Ali M. Saeed, B.S., Krishna V. Komanduri, M.D., Victor L. Perez, M.D., Robert B. Levy, Ph.D.

Blood (2013) 122 (21): 2012.

https://doi.org/10.1182/blood.V122.21.2012.2012

Published: 2013

Journal Articles

Conjunctival Biopsy to Guide Treatment of Chronic Ocular Gvhd

Pritesh R. Patel, MB, ChB, Sonal Ghandi, MD, Snehal Sonawane, MD, Sapna Tibrewal, MD, Saumad Jassim, MD, Sujata Gaitonde, MD, Santosh L Saraf, MD, Sandeep Jain, MD, Damiano Rondelli, MD

Blood (2012) 120 (21): 4491.

https://doi.org/10.1182/blood.V120.21.4491.4491

Published: 2012

Journal Articles

Phase II Study of the c-Met Inhibitor ARQ 197 (Tivantinib) in Patients with Relapsed Multiple Myeloma.

Stephan Joseph Dorkhom, D.O., Shadia Zaman, Ph.D., Sheeba K. Thomas, MD, Raymond Alexanian, M.D., Jatin J. Shah, M.D., Donna M. Weber, M.D., Michael Wang, M.D., Martha L. Anderson, R.N., Veerabhadran Baladandayuthapani, Ph.D., Yan Heather Lin, Ph.D., Min Fu, Ph.D., Christine M. Stellrecht, Ph.D., Claudia Morales de Partovi, B.S., Varsha V. Gandhi, Ph.D., Robert Z. Orlowski, M.D., Ph.D.

Blood (2012) 120 (21): 2976.

https://doi.org/10.1182/blood.V120.21.2976.2976

Published: 2012

NARROW

Clinical Manifestations and Prognostic Factors of Chronic Ocular Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation

Long-Term Morbidity Associated with Chronic Graft Vs. Host Disease (cGvHD) - a Blood or Marrow Transplant Survivor Study (BMTSS)

Idiopathic Hemochromatosis Presenting As a Sicca Syndrome. A Case Report and Review of the Literature

X4P-001: A Novel Molecularly-Targeted Oral Therapy for Whim Syndrome

Deep and Durable Responses in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (MM) Treated with Monotherapy GSK2857916, an Antibody Drug Conjugate Against B-Cell Maturation Antigen (BCMA): Preliminary Results from Part 2 of Study BMA117159

Chemotherapy-Free Induction with Ibrutinib-Rituximab Followed By Shortened Cycles of Chemo-Immunotherapy Consolidation in Young, Newly Diagnosed Mantle Cell Lymphoma Patients: A Phase II Clinical Trial

First in Human Study with GSK2857916, an Antibody Drug Conjugated to Microtubule-Disrupting Agent Directed Against B-Cell Maturation Antigen (BCMA) in Patients with Relapsed/Refractory Multiple Myeloma (MM): Results from Study BMA117159 Part 1 Dose Escalation

Ocular Graft-Versus Host Disease Prevention with Topical Cyclosporine in Non-Myeloablative Allogeneic Stem Cell Transplant

Ibrutinib Plus Rituximab in Treatment-Naive Patients with Follicular Lymphoma: Results from a Multicenter, Phase 2 Study

A Phase 1 Study of Denintuzumab Mafodotin (SGN-CD19A) in Relapsed/Refactory B-Lineage Non-Hodgkin Lymphoma

Clinical Manifestations and Treatment Results in Accordance with Frontline Treatment Modalities for Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma (OAML)

Preliminary Safety and Efficacy of the Combination of Brentuximab Vedotin and Ipilimumab in Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412)

Sorafenib Is Contributing to Salvage Chemotherapy and Is Effective Given Alone for Maintenance in AML FLT3 ITD Patients Relapsing Post Allo Hematopoietic Stem Cell Transplantation

GvHD Kinetics after Haploidentical TK-Cells: In-Vivo HSV-TK Suicide Machinery Is Effective in GvHD Control and Provide a Long-Term Immune-Suppressive Treatment-Free Survival

Ibrutinib and Rituximab Are an Efficacious and Safe Combination in Relapsed Mantle Cell Lymphoma: Preliminary Results from a Phase II Clinical Trial

Interim Analysis of a Phase 1 Study of the Antibody-Drug Conjugate SGN-CD19A in Relapsed or Refractory B-Lineage Non-Hodgkin Lymphoma

Interim Analysis of a Phase 1 Study of the Antibody-Drug Conjugate SGN-CD19A in Relapsed or Refractory B-Lineage Acute Leukemia and Highly Aggressive Lymphoma

Recruitment Of T Cells and Macrophages To The Eyes In Recipients Of Allogeneic Hematopoietic Stem Cell Transplants Correlate With Inflammatory Cytokine Presence In Ocular Gvhd

Conjunctival Biopsy to Guide Treatment of Chronic Ocular Gvhd

Phase II Study of the c-Met Inhibitor ARQ 197 (Tivantinib) in Patients with Relapsed Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only